Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ATTO | 3 | neutral | 5/10 | Multiple Form 3 initial beneficial ownership filings were filed on August 4, 2026, by major pre-IPO investors (Vida Vent | Aug 4, 2026 |
| DCOY | DEFA14A | neutral | 3/10 | Decoy Therapeutics filed a DEFA14A notice of internet availability of proxy materials for its 2026 Annual Meeting (July | Aug 4, 2026 |
| GRTX | 15-12G | neutral | 4/10 | Galera Therapeutics filed a Form 15-12G to terminate registration of its common stock under Section 12(g) following its | Aug 4, 2026 |
| RARE | 8-K | bullish | 6/10 | Ultragenyx reported Q2 2026 revenue of $214M (beat $183.1M consensus by 17%, +28% YoY) and EPS of -$0.90 (beat -$1.00 co | Aug 4, 2026 |
| RIGL | 8-K | mixed | 6/10 | Rigel Pharmaceuticals reported Q2 2026 revenue of $78.7M (net product sales $67.0M, +14% YoY) and EPS of $0.88, missing | Aug 4, 2026 |
| OKUR | 8-K | neutral | 4/10 | OnKure Therapeutics reported Q2 2026 net loss of $15.3M ($0.31/share) vs $15.4M ($1.14/share) in Q2 2025, with the per-s | Aug 4, 2026 |
| SLXN | 8-K | neutral | 4/10 | Silexion Therapeutics reported new preclinical data for SIL204, demonstrating statistically significant upregulation of | Aug 4, 2026 |
| TYRA | 424B5 | bearish | 6/10 | Tyra Biosciences has amended its existing at-the-market (ATM) equity offering agreement with TD Cowen, increasing the ma | Aug 4, 2026 |
| ATTO | 3 | neutral | 2/10 | Sanofi filed a Form 3 initial statement of beneficial ownership for Attovia Therapeutics (ATTO), disclosing ownership of | Aug 4, 2026 |
| ATTO | 3 | neutral | 2/10 | Form 3 initial beneficial ownership filing by Frazier Life Sciences entities, reporting aggregate beneficial ownership o | Aug 4, 2026 |
| IQV | CLUSTER | neutral | 4/10 | Four IQVIA insiders sold a total of ~$14.8M in shares over a 7-day window ending 7/31/2026, including a large multi-leg | Aug 4, 2026 |
| RARE | CLUSTER | neutral | 2/10 | Two C-suite insiders at Ultragenyx (CFO and EVP/Chief Legal Officer) sold a combined $164K in open-market sales on Augus | Aug 4, 2026 |
| NVO | 6-K | mixed | 6/10 | Novo Nordisk raised its full-year 2026 adjusted sales and operating profit guidance ranges from -4% to -12% to 0% to -6% | Aug 4, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a Form 6-K with an exhibit (Exhibit 99.1) titled 'Application for quotation of securities - | Aug 4, 2026 |
| LTGO | S-1/A | neutral | 6/10 | Latigo Biotherapeutics filed Amendment No. 2 to its S-1 registration statement for an IPO of 16,000,000 shares of common | Aug 4, 2026 |
| PFE | 8-K | bullish | 7/10 | Pfizer reported Q2 2026 adjusted EPS of $0.77 (12.9% beat vs $0.68 consensus) and revenue of $15.0B (4.5% beat vs $14.4B | Aug 4, 2026 |
| JUSHF | EFFECT | bearish | 5/10 | Jushi Holdings Inc. received SEC effectiveness on August 3, 2026, for two separate registration statements (File Nos. 33 | Aug 4, 2026 |
| GYRE | EFFECT | neutral | 3/10 | The SEC declared effective Gyre Therapeutics' S-3 shelf registration on August 3, 2026, covering 31,302,863 shares for r | Aug 4, 2026 |
| BDRX | EFFECT | bearish | 6/10 | Biodexa Pharmaceuticals Plc's F-1 registration statement (File No. 333-297473) became effective on August 3, 2026, allow | Aug 4, 2026 |
| IDYA | 8-K | neutral | 4/10 | IDEAYA Biosciences reported Q2 2026 results with a net loss of $112.5M ($-1.22/share), a wider loss than the prior quart | Aug 4, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a routine 6-K disclosing weekly B-share repurchase transactions under its existing DKK 15 billion buy | Aug 4, 2026 |
| IDXX | 8-K | bullish | 7/10 | IDEXX reported Q2 2026 EPS of $4.27, an 8.5% beat vs consensus of $3.93, on revenue of $1.217B (in line with $1.20B cons | Aug 4, 2026 |
| MRK | 8-K | neutral | 5/10 | Merck reported Q2 2026 revenue of $16.6B (+5% YoY), beating consensus of $16.37B, and non-GAAP EPS of -$0.13 vs consensu | Aug 4, 2026 |
| TLSA | 6-K | bullish | 5/10 | CEO Ivor Elrifi purchased 667,000 TLSA common shares at $1.00 per share on the open market, increasing his total holding | Aug 4, 2026 |
| ATTO | S-1/A | neutral | 6/10 | Attovia Therapeutics filed Amendment No. 2 to its S-1 for an IPO of 17,000,000 shares at an estimated $17.00 per share, | Aug 4, 2026 |
| ETON | 8-K | neutral | 2/10 | Eton Pharmaceuticals appointed Danka Radosavljevic, age 42, as Chief Operating Officer, effective July 31, 2026. She was | Aug 4, 2026 |
| BNTX | 6-K | bearish | 6/10 | BioNTech reported Q2 2026 revenues of €105.6M, down 60% YoY from €260.8M, driven by declining COVID-19 vaccine demand. T | Aug 4, 2026 |
| TOVX | 8-K | bearish | 4/10 | Theriva Biologics held its 2026 Annual Meeting on August 3, 2026, where stockholders approved all six proposals, includi | Aug 4, 2026 |
| NXTC | 425 | neutral | 5/10 | NextCure filed a 425 communication on August 4, 2026, publishing an Avere Therapeutics corporate presentation to potenti | Aug 4, 2026 |
| ZEOX | 8-K | neutral | 2/10 | Zeo ScientifiX announced the launch of ZEO Xperience, a three-day immersive educational conference for healthcare profes | Aug 4, 2026 |